Replimune’s rollercoaster: FDA adcom signals another bumpy rideSuggesting Replimune Group Inc.’s statistical analysis method inflated responses in the single-arm phase II Ignyte trial of RP-1 (suvolimogene oderparepvec), briefing documents ahead of the U.S. FDA’s Cellular, Tissue, and Gene Therapies advisory committee meeting on July 30 sent the company’s shares spiraling downward by about 38%.